A glass of milk each day holds the potential to improve bowel health, new research suggests. Watch this report for more details!

Glass of milk a day slashes bowel cancer risk by 17%: study

An immunotherapy drug, pembrolizumab, has shown the potential to "melt away" tumours in bowel cancer patients, as per a new&nbsp;study. It is seen to have boosted cure rates and also potentially eliminate the need for surgery, according to recent clinical trial results.

Pembrolizumab, also known as Keytruda, works by targeting and blocking a specific protein in immune cells. It enabled them to identify and destroy cancer cells.

This new approach, administered before surgery instead of chemotherapy, has yielded remarkable results.

Presented at the American Society of Clinical Oncology (ASCO) conference, the study found a substantial increase in patients achieving cancer-free status.

Also Read |&nbsp;<a href="https://www.wionews.com/science/ozempic-shows-promise-beyond-diabetes-new-study-reveals-kidney-benefits-728066">Ozempic shows promise beyond diabetes: New study reveals kidney benefits</a>

Led by researchers from University College London, University College London Hospital, the Christie NHS Foundation Trust in Manchester, St. James’s University Hospital in Leeds, University Hospital Southampton, and the University of Glasgow, the trial was funded by Merck Sharp and Dohme and included 32 patients with stage two or three bowel cancer and a specific genetic profile (MMR deficient/MSI-High bowel cancer).

Also Read |&nbsp;<a href="https://www.wionews.com/science/blood-test-predicts-breast-cancer-recurrence-years-in-advance-728065">Blood test predicts breast cancer recurrence years in advance</a>

The trial results were described as "really very exciting" by Professor Mark Saunders, a consultant clinical oncologist at the Christie.

"Immunotherapy prior to surgery could well become a 'gamechanger' for these patients with this type of cancer. Not only is the outcome better, but it saves patients from having more conventional chemotherapy, which often has more side-effects. In the future, immunotherapy may even replace the need for surgery."

Bowel cancer is a significant global health issue, being the second leading cause of cancer-related deaths worldwide with over 1.9 million new cases and more than 900,000 deaths annually, according to the World Health Organization.

Watch | Gravitas: Japanese researchers closer to make biological clock irrelevant

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-japanese-researchers-closer-to-make-biological-clock-irrelevant-724054/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<h2>Trial&nbsp;</h2>

During the trial, patients received pembrolizumab for nine weeks before surgery, bypassing the traditional chemotherapy route. The results were striking. About 59 per cent of patients had no signs of cancer following the treatment, while the remaining 41 per cent had their cancer surgically removed.

All patients in the trial were cancer-free post-treatment.&nbsp;

Dr. Kai-Keen Shiu, the trial’s chief investigator highlighted the drug’s efficacy saying, "Our results indicate that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers, increasing the chances of curing the disease at an early stage."

He noted that while the initial results are promising, long-term follow-up is necessary to confirm the durability of the response.

(With inputs from agencies)

An immunotherapy drug, pembrolizumab, has shown the potential to "melt away" tumours in bowel cancer patients, as per a new study. It is seen to have boosted cure rates and also potentially eliminate the need for surgery, according to recent clinical trial results.

An immunotherapy drug, pembrolizumab, has shown the potential to "melt away" tumours in bowel cancer patients, as per a new study. It is seen to have boosted cure rates and also potentially eliminate the need for surgery, according to recent clinical trial results. Pembrolizumab, also known as Keytruda, works by targeting and blocking a specific protein in immune cells. It enabled them to identify and destroy cancer cells. This new approach, administered before surgery instead of chemotherapy, has yielded remarkable results. Presented at the American Society of Clinical Oncology (ASCO) conference, the study found a substantial increase in patients achieving cancer-free status. Also Read | Ozempic shows promise beyond diabetes: New study reveals kidney benefits Led by researchers from University College London, University College London Hospital, the Christie NHS Foundation Trust in Manchester, St. James’s University Hospital in Leeds, University Hospital Southampton, and the University of Glasgow, the trial was funded by Merck Sharp and Dohme and included 32 patients with stage two or three bowel cancer and a specific genetic profile (MMR deficient/MSI-High bowel cancer). Also Read | Blood test predicts breast cancer recurrence years in advance The trial results were described as "really very exciting" by Professor Mark Saunders, a consultant clinical oncologist at the Christie. "Immunotherapy prior to surgery could well become a 'gamechanger' for these patients with this type of cancer. Not only is the outcome better, but it saves patients from having more conventional chemotherapy, which often has more side-effects. In the future, immunotherapy may even replace the need for surgery." Bowel cancer is a significant global health issue, being the second leading cause of cancer-related deaths worldwide with over 1.9 million new cases and more than 900,000 deaths annually, according to the World Health Organization. Watch | Gravitas: Japanese researchers closer to make biological clock irrelevant × Trial During the trial, patients received pembrolizumab for nine weeks before surgery, bypassing the traditional chemotherapy route. The results were striking. About 59 per cent of patients had no signs of cancer following the treatment, while the remaining 41 per cent had their cancer surgically removed. All patients in the trial were cancer-free post-treatment. Dr. Kai-Keen Shiu, the trial’s chief investigator highlighted the drug’s efficacy saying, "Our results indicate that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers, increasing the chances of curing the disease at an early stage." He noted that while the initial results are promising, long-term follow-up is necessary to confirm the durability of the response. (With inputs from agencies)

THIS immunotherapy drug could revolutionise bowel cancer treatment

A recent research has revealed&nbsp;that people with bowel cancer who consume two to four cups of coffee daily are significantly less likely to experience disease recurrence and have a reduced risk of mortality from any cause. This suggests a potential benefit of coffee consumption for individuals diagnosed with bowel cancer, the UK's second-leading cancer killer, according to the study&nbsp;<a data-link-name="in body link" href="https://onlinelibrary.wiley.com/doi/10.1002/ijc.34879">published in the International Journal of Cancer</a>.

The study conducted in the Netherlands, involving&nbsp;1,719 bowel cancer patients, demonstrated a dose-dependent relationship between coffee consumption and disease recurrence. Those who consumed at least two cups daily experienced a lower risk of cancer recurrence, with the greatest reduction observed among those consuming five or more cups per day.

<h2>Impact on survival</h2>

Higher coffee intake was also associated with improved survival rates among bowel cancer patients. Individuals consuming at least two cups daily had a lower risk of mortality compared to non-coffee drinkers, with the most significant reduction seen among those consuming five or more cups per day.

The findings offer promise, suggesting that regular coffee consumption may benefit individuals diagnosed with bowel cancer. If corroborated by further studies, this could potentially influence the behaviour of the 43,000 Britons diagnosed with bowel cancer annually. Given the disease's significant toll – claiming approximately 16,500 lives annually – such interventions could have profound implications.

<a href="https://www.wionews.com/science/moderate-consumption-of-tea-coffee-linked-to-decreased-risks-of-cognitive-disorders-study-655274">Also read |&nbsp;Moderate consumption of tea, coffee linked to decreased risks of cognitive disorders: Study</a>

Dr&nbsp;Ellen Kampman, the study's lead researcher, spoke to the Guardian about&nbsp;the potential impact of coffee consumption on reducing bowel cancer recurrence. While cautioning against definitive causal conclusions, she highlighted the dose-dependent nature of the observed effects, suggesting a potential real association.

“It’s intriguing that that this study suggests drinking three to four cups of coffee may reduce the recurrence of bowel cancer,” she said.

Also watch |&nbsp;Will you drink a coffee made through animal poop?

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/will-you-drink-a-coffee-made-through-animal-poop-464843/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Further research is needed to unravel the biological mechanisms underlying coffee's potential protective effects against bowel cancer. The World Cancer Research Fund (WCRF) has identified chlorogenic acid, found in coffee and kale, as a promising candidate due to its role in glucose and insulin regulation.

(With inputs from agencies)

A recent research has revealed that people with bowel cancer who consume two to four cups of coffee daily are significantly less likely to experience disease recurrence and have a reduced risk of mortality from any cause.

A recent research has revealed that people with bowel cancer who consume two to four cups of coffee daily are significantly less likely to experience disease recurrence and have a reduced risk of mortality from any cause. This suggests a potential benefit of coffee consumption for individuals diagnosed with bowel cancer, the UK's second-leading cancer killer, according to the study published in the International Journal of Cancer. The study conducted in the Netherlands, involving 1,719 bowel cancer patients, demonstrated a dose-dependent relationship between coffee consumption and disease recurrence. Those who consumed at least two cups daily experienced a lower risk of cancer recurrence, with the greatest reduction observed among those consuming five or more cups per day. Impact on survival Higher coffee intake was also associated with improved survival rates among bowel cancer patients. Individuals consuming at least two cups daily had a lower risk of mortality compared to non-coffee drinkers, with the most significant reduction seen among those consuming five or more cups per day. The findings offer promise, suggesting that regular coffee consumption may benefit individuals diagnosed with bowel cancer. If corroborated by further studies, this could potentially influence the behaviour of the 43,000 Britons diagnosed with bowel cancer annually. Given the disease's significant toll – claiming approximately 16,500 lives annually – such interventions could have profound implications. Also read | Moderate consumption of tea, coffee linked to decreased risks of cognitive disorders: Study Dr Ellen Kampman, the study's lead researcher, spoke to the Guardian about the potential impact of coffee consumption on reducing bowel cancer recurrence. While cautioning against definitive causal conclusions, she highlighted the dose-dependent nature of the observed effects, suggesting a potential real association. “It’s intriguing that that this study suggests drinking three to four cups of coffee may reduce the recurrence of bowel cancer,” she said. Also watch | Will you drink a coffee made through animal poop? Further research is needed to unravel the biological mechanisms underlying coffee's potential protective effects against bowel cancer. The World Cancer Research Fund (WCRF) has identified chlorogenic acid, found in coffee and kale, as a promising candidate due to its role in glucose and insulin regulation. (With inputs from agencies)

Drinking two to four cups of coffee a day can lower risk of bowel cancer recurrence: Study

The consumption of sugary drinks has exploded worldwide in <a href="https://www.wionews.com/world/cancer-deaths-over-last-5-years-falling-in-european-union-study-204192">recent decades and the high-calorie</a> beverages have already been associated with a elevated risk of obesity -&nbsp;itself recognised as a leading cancer risk factor.

A team of researchers in France wanted to assess the associations between heightened consumption of sugar drinks and the risks of overall cancer, as well as several cancer types, including breast, prostate and bowel cancers.

They surveyed more than 100,000 adults, with an average of age of 42, 79 per cent of whom were women.&nbsp;

The participants, who were followed for a maximum of nine years, completed at least two 24-hour online validated dietary questionnaires, calculating their daily consumption of sugar and artificially sweetened beverages as well as 100 per cent fruit juices.

Researchers measured the daily intakes of sugary drinks against those of diet beverages and compared them to cancer cases in participants' medical records during the follow-up period.

They found that just a 100 ml increase per day of sugary drinks was associated with an 18 per cent increased risk of cancer, and with a 22 per cent increase in breast cancer.&nbsp;

Both sugar-sweetened drinks and fruit juices saw a similar higher risk association.&nbsp;

During a follow-up, researchers found 2,193 cases of cancer were diagnosed, the average age at diagnosis being 59 years.&nbsp;

Authors of the study, which appeared in the BMJ medical journal, stressed their work was based on observation and so could not establish the cause of cancer prognoses.&nbsp;

But the sample size was large and they adjusted for a number of other influential factors.

Its authors suggested that, based on their findings, taxing sugary products could have a significant impact on cancer rates.&nbsp;

"This large, well-designed study adds to the existing evidence that consumption of sugary drinks may be associated with increased risk of some cancers," Graham Wheeler, senior statistician of the Cancer Research UK said of the study.

The consumption of sugary drinks has exploded worldwide in recent decades and the high-calorie beverages have already been associated with a elevated risk of obesity - itself recognised as a leading cancer risk factor.

The consumption of sugary drinks has exploded worldwide in recent decades and the high-calorie beverages have already been associated with a elevated risk of obesity - itself recognised as a leading cancer risk factor. A team of researchers in France wanted to assess the associations between heightened consumption of sugar drinks and the risks of overall cancer, as well as several cancer types, including breast, prostate and bowel cancers. They surveyed more than 100,000 adults, with an average of age of 42, 79 per cent of whom were women. The participants, who were followed for a maximum of nine years, completed at least two 24-hour online validated dietary questionnaires, calculating their daily consumption of sugar and artificially sweetened beverages as well as 100 per cent fruit juices. Researchers measured the daily intakes of sugary drinks against those of diet beverages and compared them to cancer cases in participants' medical records during the follow-up period. They found that just a 100 ml increase per day of sugary drinks was associated with an 18 per cent increased risk of cancer, and with a 22 per cent increase in breast cancer. Both sugar-sweetened drinks and fruit juices saw a similar higher risk association. During a follow-up, researchers found 2,193 cases of cancer were diagnosed, the average age at diagnosis being 59 years. Authors of the study, which appeared in the BMJ medical journal, stressed their work was based on observation and so could not establish the cause of cancer prognoses. But the sample size was large and they adjusted for a number of other influential factors. Its authors suggested that, based on their findings, taxing sugary products could have a significant impact on cancer rates. "This large, well-designed study adds to the existing evidence that consumption of sugary drinks may be associated with increased risk of some cancers," Graham Wheeler, senior statistician of the Cancer Research UK said of the study.

Just 100 ml consumption of sugary drinks can increase cancer risk: Study

bowel-cancer

Bowel Cancer, News on Bowel Cancer, stories on Bowel Cancer, articles on Bowel Cancer, Bowel Cancer stories at Wion, Bowel Cancer news, Bowel Cancer latest news